<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00419653</url>
  </required_header>
  <id_info>
    <org_study_id>001</org_study_id>
    <nct_id>NCT00419653</nct_id>
  </id_info>
  <brief_title>Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy</brief_title>
  <official_title>Modulation of Regional Brain Activation in Schizophrenic Patients by Pharmacological Therapy With Amisulpride, Olanzapine or Haloperidol. A Study With Functional Magnetic Resonance Imaging (fMRI) and Diffusion Tensor Imaging (DTI)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Jena</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Jena</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study aims to investigate the modulation of regional brain activation in schizophrenic
      patients by psychopharmacological treatment with either haloperidol, amisulpride or
      olanzapine. The study will be performed with functional magnetic resonance imaging (fMRI) and
      diffusion tensor imaging (DTI).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current study aims to investigate the following issues:

        -  Changes in cognitive activation patterns under therapy with the typical neuroleptic
           haloperidol as compared to the atypical antipsychotics amisulpride and olanzapine

        -  Relationship of these changes in activity to psychopathological, neuropsychological and
           pharmacotherapeutic variables (e.g. drug plasma level) as well as to certain biological
           markers (HVA, prolactin)

        -  Relationship between diffusion anisotropy as an indicator for structural connectivity
           and cognitive activation patterns under antipsychotic treatment
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Recruitment issues
  </why_stopped>
  <start_date>January 2003</start_date>
  <completion_date type="Actual">September 2007</completion_date>
  <primary_completion_date type="Actual">September 2007</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Activation/deactivation in fMRI</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">19</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Haloperidol</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Haloperidol</intervention_name>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  In- and outpatients of either sex

          -  Able to comply with the protocol

          -  Having given their written informed consent of their own free will

          -  Total BPRS (PANSS-derived, 1-7 points) minimum 36 points at baseline

          -  Schizophrenic or schizophreniform disorder according to DSM-IV criteria (295.10, .30,
             .40, .90)

          -  Definite right-handedness (according to the modified Edinburgh Handedness Inventory)

          -  Age 18 - 50 years

        Exclusion Criteria:

          -  Co-morbid psychiatric axis I disorder (DSM-IV) other than schizophrenia

          -  Axis II disorder according to DSM-IV

          -  Present or past history of substance and drug dependence (including alcohol
             dependence)

          -  Participation in a clinical trial within the previous three months

          -  Lack of insight

          -  Suicidal ideations or aggression against others

          -  Consumption of caffeine-containing beverages within 6 hours before assessments

          -  Clinically significant findings in ECG or EEG

          -  Known intolerance against neuroleptics
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ralf Schlösser, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>FSU Jena</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <verification_date>September 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 8, 2007</study_first_submitted>
  <study_first_submitted_qc>January 8, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 9, 2007</study_first_posted>
  <last_update_submitted>September 15, 2008</last_update_submitted>
  <last_update_submitted_qc>September 15, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 16, 2008</last_update_posted>
  <responsible_party>
    <name_title>Dr. Ralf Schlösser</name_title>
    <organization>University of Jena</organization>
  </responsible_party>
  <keyword>schizophrenia fMRI drug therapy amisulpride</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Haloperidol</mesh_term>
    <mesh_term>Haloperidol decanoate</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

